Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Staats, Herman F ^a   Fielhauer, Jeffrey R ^a   Thompson, Afton L ^a   Tripp, Alice A ^a   Sobel, Ashley E ^a   Maddaloni, Massimo ^b   Abraham, Soman N ^a   Pascual, David W ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A SUBUNIT VACCINE; COMPOUND 48-80; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; BACTERIAL VACCINE; BOTULINUM TOXIN A; IMMUNOLOGICAL ADJUVANT; NEUROTOXIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; ANIMAL; BIOSYNTHESIS; DRUG DELIVERY SYSTEM; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MAST CELL; METHODOLOGY; MUCOSA;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; DRUG DELIVERY SYSTEMS; MAST CELLS; MICE; MUCOUS MEMBRANE; NEUROTOXINS; RABBITS; VACCINES, SUBUNIT;

EID: 79551554495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016532     Document Type: Article

References (68)

1. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nature Structural Biology 5: 898-902.
2. Krieglstein KG, DasGupta BR, Henschen AH (1994) Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. Journal of Protein Chemistry 13: 49-57.
3. Ginalski K, Venclovas C, Lesyng B, Fidelis K (2000) Structure-based sequence alignment for the Beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Letters 482: 119-124.
4. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum Toxin as a Biological Weapon: Medical and Public Health Management. JAMA 285: 1059-1070.
5. Smith LA (2009) Botulism and vaccines for its prevention. Vaccine 27 (Suppl 4): D33-39.
6. Rusnak JM, Smith LA (2009) Botulinum neurotoxin vaccines: Past history and recent developments. Hum Vaccin 5.
7. Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robinson A, et al. (2006) Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 177: 5524-5532.
8. Wu HY, Nguyen HH, Russell MW (1997) Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scandinavian Journal of Immunology 46: 506-513.
9. Wu HY, Russell MW (1997) Nasal Lymphoid Tissue, Intranasal Immunization, and Compartmentalization of the Common Mucosal Immune System. Immunologic Research 16: 187-201.
10. Zuercher AW, Cebra JJ (2002) Structural and functional differences between putative mucosal inductive sites of the rat. European Journal of Immunology 32: 3191-3196.
11. Bienenstock J, McDermott MR (2005) Bronchus- and nasal-associated lymphoid tissues. Immunological Reviews 206: 22-31.
12. Kiyono H, Fukuyama S (2004) NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4: 699-710.
13. Debertin AS, Tscherning T, Tonjes H, Kleemann WJ, Troger HD, et al. (2003) Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin Exp Immunol 134: 503-507.
14. Casteleyn C, Broos AM, Simoens P, Van den Broeck W (2010) NALT (nasal cavity-associated lymphoid tissue) in the rabbit. Vet Immunol Immunopathol 133: 212-218.
15. Brandtzaeg P (2003) Immunology of tonsils and adenoids: everything the ENT surgeon needs to know. International Journal of Pediatric Otorhinolaryngology 67: S69-S76.
16. Boyaka PN, Wright PF, Marinaro M, Kiyono H, Johnson JE, et al. (2000) Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am J Pathol 157: 2023-2035.
17. McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, et al. (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nature Medicine 14: 536-541.
18. McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF (2009) The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27: 3544-3552.
19. Snider DP, Marshall JS, Perdue MH, Liang H (1994) Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. Journal of Immunology 153: 647-657.
20. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR (2000) Cutting Edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. The Journal of Immunology 165: 4778-4782.
21. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, et al. (1995) Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. Journal of Immunology 155: 4621-4629.
22. Simecka JW, Jackson RJ, Kiyono H, McGhee JR (2000) Mucosally Induced Immunoglobulin E-Associated Inflammation in the Respiratory Tract. Infect Immun 68: 672-679.
23. Couch RB (2004) Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. [comment]. New England Journal of Medicine 350: 860-861.
24. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. [see comment]. New England Journal of Medicine 350: 896-903.
25. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4: e6999.
26. Staats HF, Alam SM, Scearce RM, Kirwan SM, Zhang JX, et al. (2007) In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun 75: 5443-5452.
27. Nordone SK, Peacock JW, Kirwan SM, Staats HF (2006) Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Research and Human Retroviruses 22: 558-568.
28. Bradney CP, Sempowski GD, Liao H-X, Haynes BF, Staats HF (2002) Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization. J Virol 76: 517-524.
29. Chen D, Zuleger C, Chu Q, Maa YF, Osorio J, et al. (2002) Epidermal Powder Immunization with a Recombinant HIV gp120 Targets Langerhans Cells and Induces Enhanced Immune Responses. AIDS Research and Human Retroviruses 18: 715-722.
30. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, et al. (2002) Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 76: 2835-2847.
31. McCloskey N, Turner MW, Goldblatt TD (1997) Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). Journal of Immunological Methods 205: 67-72.
32. Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, et al. (2005) Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infection & Immunity 73: 6998-7005.
33. Smith LA, Rusnak JM (2007) Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27: 303-318.
34. Singh BR, DasGupta BR (1989) Molecular differences between type A botulinum neurotoxin and its toxoid. Toxicon 27: 403-410.
35. Heimsch RC, Champion LA, Sugiyama H (1970) Botulinal toxin and toxoid as antigens. Proceedings of the Society for Experimental Biology & Medicine 135: 151-154.
36. Olszewska W, Obeid OE, Steward MW (2000) Protection against measles virusinduced encephalitis by anti-mimotope antibodies: the role of antibody affinity. Virology 272: 98-105.
37. Marks JD (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Movement Disorders 19.
38. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, et al. (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nature Biotechnology 20: 597-601.
39. Kermode M (2004) Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 19: 95-103.
40. Allegranzi B, Storr J, Dziekan G, Leotsakos A, Donaldson L, et al. (2007) The First Global Patient Safety Challenge ''Clean Care is Safer Care'': from launch to current progress and achievements. Journal of Hospital Infection 65(Suppl 2): 115-123.
41. Reid S (2009) Increase in clinical prevalence of AIDS implies increase in unsafe medical injections. Int J STD AIDS 20: 295-299.
42. WHO (2002) Fact Sheet 231. SAFETY OF INJECTIONS. Misuse and overuse of injection worldwide.
43. Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, et al. (2001) Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 19: 1594-1605.
44. Nir Y, Paz A, Sabo E, Potasman I (2003) Fear of injections in young adults: prevalence and associations. American Journal of Tropical Medicine and Hygiene 68: 341-344.
45. Aggerbeck H, Gizurarson S, Wantzin J, Heron I (1997) Intranasal Booster Vaccination Against Diphtheria and Tetanus in Man. Vaccine 15: 307-316.
46. Millner VS, Eichold BH, 2nd, Franks RD, Johnson GD (2010) Influenza vaccination acceptance and refusal rates among health care personnel. Southern Medical Journal 103: 993-998.
47. Beyer WE, Palache AM, de Jong JC, Osterhaus AD (2002) Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. [see comment]. Vaccine 20: 1340-1353.
48. Cox RJ, Brokstad KA, Ogra P (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology 59: 1-15.
49. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484.
50. Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, et al. (2010) Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine 28: 6901-6914.
51. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, et al. (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9: 572-578.
52. Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E (2005) Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. Journal of Virology 79: 11627-11637.
53. Harris SL, King WJ, Ferris W, Granoff DM (2003) Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun 71: 275-286.
54. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, et al. (2002) Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 70: 584-590.
55. Schlesinger Y, Granoff DM (1992) Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. Jama 267: 1489-1494.
56. Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF (2002) Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 76: 517-524.
57. Staats HF, Nichols WG, Palker TJ (1996) Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 157: 462-472.
58. Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, et al. (2005) A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 174: 2190-2195.
59. Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, et al. (2010) Effective induction of protective systemic immunity with nasally-administered vaccines adjuvanted with IL-1. Vaccine.
60. Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, et al. (2004) A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22: 3774-3788.
61. Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, et al. (2007) Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccines 3: 90-93.
62. Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, et al. (2009) Spraydried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 27: 1279-1286.
63. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, et al. (2003) Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen. J Immunol 170: 5636-5643.
64. Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, et al. (2010) Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. American Journal of Obstetrics and Gynecology.
65. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, et al. (2010) Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 5: e13755.
66. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, et al. (2009) Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28: 228-234.
67. Newman SP, Pitcairn GR, Dalby RN (2004) Drug delivery to the nasal cavity: in vitro and in vivo assessment. Critical Reviews in Therapeutic Drug Carrier Systems 21: 21-66.
68. Kleinstreuer C, Zhang Z, Donohue JF (2008) Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 10: 195-220.